Oncorus, Inc.: Nasdaq/NYSE listing notice — Oncorus to dissolve and liquidate; Nasdaq delisting effective June 20, 2023

Oncorus, Inc.

Board unanimously approved dissolution and liquidation plan, subject to stockholder approval.
Workforce reduction impacting substantially all remaining employees, expected completion by August 2023.
Nasdaq determined company is a public shell; continued listing no longer warranted.
Company will not appeal; trading suspension expected at open on June 20, 2023.
Nasdaq will file Form 25-NSE to remove common stock from listing and registration.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Oncorus, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101

Exact text from the filing

June 8, 2023, the Company received written notice from The Nasdaq Stock Market LLC (" Nasdaq ") that, in light of the Plan of Dissolution, the Workforce Reduction Plan and based upon Nasdaq’s review of the Company and pursuant to Nasdaq Listing Rule 5101, Nasdaq believes that the Company is a “public shell,” and that the continued listing of its securities is no longer warranted. The Company does not plan to appeal Nasdaq’s determination. Therefore, the Company expects, based on Nasdaq’s written notice, that the trading of its common stock will be suspended as of the opening of business on Jun

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-027274

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.